Researcher
Paul Cos
- Research Expertise:In vitro and in vivo biofilm assays, Integrated antimicrobial (bacteria, fungi, yeasts and parasites) screening and profiling of pure compounds and extracts, targeting redox homeostasis in mycobacteria
- Keywords:MICROBIOLOGY, BACTERIOLOGY, BIOFILMS, INFLAMMATION, Pharmacy and pharmacology
- Disciplines:Microbiology, Systems biology, Laboratory medicine
- Research techniques:In vitro and in vivo (pre-clinical) models of infectious diseases (bacteria and fungi), evaluation of drugs
- Users of research expertise:Pharmaceutical companies (big pharma, SME, spin-off), news agencies, journalists, government agencies, regulatory (EU) agencies, non-governmental organisations in the field of infectious diseases
Affiliations
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH) (Research group)
Responsible
From1 Oct 2020 → Today - Laboratory for Microbiology, Parasitology and Hygiene (LMPH) (Research group)
Member
From1 Oct 2006 → 30 Sep 2020
Projects
51 - 59 of 59
- Biology and ecology of bacterial and fungal biofilms in humans.From1 Jan 2011 → 31 Dec 2020Funding: FWO scientific research network
- Applicability of dipeptidyl peptidase inhibitors as an anti-virulence therapy in Porphyromonas gingivalis infections.From1 Jan 2011 → 31 Dec 2014Funding: IWT personal funding - strategic basic research grants
- In vitro and in vivo study of mono- and polymicrobial biofilms as a major cause of therapeutic failure in intensive care units (ICU).From1 Oct 2010 → 30 Sep 2012Funding: FWO fellowships
- Long-term monitoring for drug resistance of visceral leishmaniasis caused by Leishmania infantum in HIV patients.From1 Jan 2010 → 31 Dec 2010Funding: Research funding concerning international, bilateral and/or cultural agreements
- Study of the intestinal mucosal response and oxidative stress on the course of Giardia duodenalis infections.From1 Oct 2009 → 30 Sep 2011Funding: FWO fellowships
- Research on bacterial virulence inhibitors with predictive in vitro and in vivo models.From1 Jul 2009 → 31 Dec 2013Funding: BOF - Doctoral projects
- Bacterial virulence as new target for protease inhibitors.From1 Jan 2009 → 31 Dec 2012Funding: FWO research project (including WEAVE projects)
- The role of oxidative stress in infection dynamics and treatment of leishmaniasis.From1 Oct 2008 → 30 Sep 2011Funding: FWO fellowships
- Protective gastro-intestinal effects of bovine milk fat globule membrane (MFGM) glycoproteins.From1 Jan 2008 → 31 Dec 2011Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 272
- In vitro modelling of bacterial pneumonia(2024)
Authors: Laure Mahieu, Laurence Van Moll, Linda De Vooght, Peter Delputte, Paul Cos
Pages: 1 - 23 - A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors(2024)
Authors: Natalia Smiejkowska, Lauren Oorts, Linda De Vooght, Rob Geens, Henri-Philippe Mattelaer, Koen Augustyns, Sergei V. Strelkov, Dirk Lamprecht, Koen Temmerman, Yann Sterckx, et al.
Pages: 1 - 22 - Mycothione reductase as a potential target in the fight against Mycobacterium abscessus infections(2024)
Authors: Linda De Vooght, Y. Gansemans, F. Van Nieuwerburgh, Paul Cos
Pages: 1 - 14 - All eyes on the prefusion-stabilized F construct, but are we missing the potential of alternative targets for respiratory syncytial virus vaccine design?(2024)
Authors: Lotte Jacobs, Kim Stobbelaar, Paul Cos, Peter Delputte
Pages: 1 - 27 - Bioinsecticide potential of ethanol extracts from Persea americana (Lauraceae) seeds on Aedes aegypti mosquitoes(2023)
Authors: Silvia Molina Bertrán, Idelsy Chil-Nunez, Julio Cesar Escalona-Arranz, Raimundo Nonato Picanco-Souto, Alejandro Felipe Gonzalez, Jesus Garcia Diaz, Paul Cos, Gabriel Llauradó Maury, Humberto Joaquin Morris-Quevedo
Pages: 404 - 414 - Selected strategies to fight pathogenic bacteria(2023)
Authors: Aiva Plotniece, Arkadij Sobolev, Claudiu T. Supuran, Fabrizio Carta, Fredrik Björkling, Henrik Franzyk, Jari Yli-Kauhaluoma, Koen Augustyns, Paul Cos, Linda De Vooght, et al.
Pages: 1 - 27 - In vitro persistence level reflects In vivo antibiotic survival of natural Pseudomonas aeruginosa isolates in a murine lung infection model(2023)
Authors: Laure Verstraete, Juliana Aizawa Porto de Abreu, Matthias Govaerts, Linda De Vooght, Rob Lavigne, Jan Michiels, Bram van den Bergh, Paul Cos
Pages: 1 - 17 - Development and validation of a multiplex electrochemiluminescence immunoassay to evaluate dry eye disease in rat tear fluids(2023)
Authors: Agnese Compagnone, Linda De Vooght, Paul Cos
Pages: 1 - 15 - Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents(2023)
Authors: Charlotte Courtens, Frits van Charante, Thibaut Quennesson, Martijn Risseeuw, Paul Cos, Guy Caljon, Tom Coenye, Serge Van Calenbergh
Pages: 1 - 14 - In-depth biological characterization of two black soldier fly anti- Pseudomonas peptides reveals LPS-binding and immunomodulating effects(2023)
Authors: Laurence Van Moll, Milan Wouters, Jeroen De Smet, Linda De Vooght, Peter Delputte, Mik Van Der Borght, Paul Cos
Pages: 1 - 15
Patents
1 - 5 of 5
- Compositions against candida infections (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Compositions against candida infections (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)